Related Experiment Videos

Gastroprotective Effects of a Polyherbal Formulation (HF33) in Experimental Gastric Ulcer Models and Its Acute Oral

Natthakarn Chiranthanut¹, Sunee Chansakaow², Phraepakaporn Kunnaja³

¹Department of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.

Pharmaceuticals (Basel, Switzerland)

|October 27, 2026

Abstract:

Background/Objectives: HF33 is a polyherbal formulation developed from Thai folk medicinal knowledge for the management of dyspepsia and gastric ulcer-like symptoms. Its gastroprotective activity and underlying mechanisms have not been systematically investigated. This study aimed to characterize the HF33 formulation and evaluate the gastroprotective activity, possible mechanisms of action, and acute oral toxicity of its ethanolic extract. Methods: HF33 formulation powder was characterized according to the Thai Herbal Pharmacopoeia using pharmacognostic, physicochemical, and HPLC-PDA analyses, and the extract was chemically fingerprinted by compact mass spectrometry. Antioxidant activity and total phenolic and flavonoid contents were determined. Gastroprotective activity of the extract (150, 300, and 600 mg/kg, p.o.) was evaluated in male Sprague-Dawley rats using restraint water immersion stress-, indomethacin-, and acidified ethanol (EtOH/HCl)-induced gastric ulcer models. Histopathology, MDA and SOD, gastric mucus content, and gastric secretion parameters were assessed. Acute oral toxicity was evaluated in female Sprague-Dawley rats according to OECD Test Guideline 420. Results: Quality characterization established the identity and quality attributes of the HF33 formulation and its extract prior to biological evaluation. The HF33 extract exhibited in vitro antioxidant activity and significantly reduced gastric lesion formation in all three ulcer models. Gastroprotection was associated with preservation of gastric mucosal architecture, increased gastric mucus content, reduced MDA levels, and restored SOD activity, without significant alteration of gastric secretion parameters. No treatment-related toxicity was observed following a single oral administration of 2000 mg/kg. Conclusions: The HF33 ethanolic extract exhibited gastroprotective activity across multiple experimental gastric ulcer models. The protective activity was associated with preservation of mucosal integrity, enhancement of the mucus barrier, and attenuation of oxidative damage without affecting gastric acid secretion. These findings support further preclinical investigation of HF33 as a quality-characterized polyherbal formulation with potential gastroprotective properties.

Keywords:

HF33 acute oral toxicity gastric ulcer gastroprotective activity oxidative stress polyherbal formulation

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.

Gastritis III: Clinical Manifestations and Management

Gastritis III: Clinical Manifestations and Management

The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

Peptic Ulcer Disease IV: Management

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...

Articles linked to this work by shared authors, journal, and citation graph.

Detoxifying Effects of a Phenolic-Rich Thunbergia laurifolia Water Extract Against Chlorpyrifos-Induced Oxidative Stress: Evidence from an Integrated In Vitro and In Vivo Study.

International journal of molecular sciences·2026

Mucuna pruriens var. pruriens Ethanolic Seed Extract Enhances Erectile Function-Related Mechanisms: Integrated In Vitro and In Vivo Evidence.

Biology·2026

Effects of CYP3A4, CYP3A5, and ABCB1 genetic variants on tacrolimus metabolism during the early period after kidney transplantation.

The pharmacogenomics journal·2026

Effects of curcuminoids on allergic rhinitis diseases: a systematic review and meta-analysis of animal and human studies.

Systematic reviews·2026

In Situ Thai Apis mellifera Propolis Film as Potential Protective Phytopharmaceuticals Against UVB-Induced HaCaT Keratinocyte Damage.

Pharmaceuticals (Basel, Switzerland)·2026

Bridging Traditional Wisdom and Evidence-Based Pharmaceutics: Comprehensive Specification and Biological Activity of the Wannachawee Recipe for Psoriasis.

Plants (Basel, Switzerland)·2026

See all related articles